Oral VV261 administration protects mice from lethal Crimean-Congo hemorrhagic fever virus challenge

  • J Virol. 2025 Dec 23;99(12):e0158325. doi: 10.1128/jvi.01583-25.
Xi Wang  #  1 ,  Huan Xu  #  1  2 ,  Liushuai Li  1 ,  Fan Wu  1 ,  Jiang Li  1 ,  Jingshan Shen  3 ,  Gengfu Xiao  1 ,  Wei Zheng  4 ,  Leike Zhang  1 ,  Zhihong Hu  1 ,  Manli Wang  1
Affiliations
  • 1. State Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.
  • 2. Department of Pediatrics, Union Hospital, Tongji Medical college, Huazhong University of Science and Technology, Wuhan, China.
  • 3. State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • 4. Vigonvita Shanghai Co., Ltd, Shanghai, China.
  • # Contributed equally.
PMID: 41288381 DOI: 10.1128/jvi.01583-25
Keywords
Crimean-Congo hemorrhagic fever virus; VV261; nucleoside analog; oral administration.
Products